SCHEMBL4278286

SCHEMBL4278286

C=CC(N)C1=Cc2ccccc2C(=O)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.57
CDC25A P30304 1/20 0.57
PTPRC P08575 7/20 0.39
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
LMNA P02545 4/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
POLB P06746 3/20 0.39
S100A4 P26447 3/20 0.39
APAF1 O14727 3/20 0.39
HTT P42858 3/20 0.39
GALK1 P51570 3/20 0.39
BLM P54132 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
MAPT P10636 3/20 0.39
THRB P10828 3/20 0.39
MAOA P21397 3/20 0.39
TDP2 O95551 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133450 0.76 PTPN1 (0.55) CDC25BPTPRCMEN1KMT2ALMNA
SCHEMBL24224703 0.73 CDC25B (1.00) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL31619928 0.67 CDC25B (0.89) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL11828689 0.67 CDC25B (0.89) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL6233550 0.66 CDC25B (0.52) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL30003397 0.66 CDC25B (0.52) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL4310782 0.66 CDC25A (0.56) CDC25BCDC25APTPRCMEN1KMT2A
SCHEMBL8607876 0.65 MAOA (0.56) CDC25BPTPRCMEN1KMT2ALMNA
SCHEMBL11585770 0.64 ADORA2A (0.50) CDC25BPTPRCMEN1KMT2ALMNA
SCHEMBL5656918 0.64 MEN1 (0.32) CDC25BCDC25APTPRCMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215145-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE MD BIOALPHA CO., LTD. (KR) 2009-08-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215145-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE NQO1, NADK, ME2 CDC25B 2415/4885CDC25A 1750/4885PTPRC 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.